Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.

about

Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA).

P2860

Q55451692-1D311F4B-9228-4EBE-B4AD-6239CACDF1F6

P2860

Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q51146815

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Oral arsenic trioxide-based re ...... fractory mantle cell lymphoma.

@en

Oral arsenic trioxide-based re ...... fractory mantle cell lymphoma.

@nl

type

Item

label

Oral arsenic trioxide-based re ...... fractory mantle cell lymphoma.

@en

Oral arsenic trioxide-based re ...... fractory mantle cell lymphoma.

@nl

prefLabel

Oral arsenic trioxide-based re ...... fractory mantle cell lymphoma.

@en

Oral arsenic trioxide-based re ...... fractory mantle cell lymphoma.

@nl

P1476

Oral arsenic trioxide-based re ...... efractory mantle cell lymphoma

@en

P2093

H Gill

http://www.w3.org/2001/XMLSchema#string

W W Cheung

http://www.w3.org/2001/XMLSchema#string

W Y Au

http://www.w3.org/2001/XMLSchema#string

Y L Kwong

http://www.w3.org/2001/XMLSchema#string

P2860

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group

P304

1391-1397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDU142

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elaine Yuen Phin Lee

P577

2014-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261609318

http://www.w3.org/2001/XMLSchema#string

P698

24728036

http://www.w3.org/2001/XMLSchema#string

Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.

about

P2860

P2860

Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698